ROCO
1777
Market cap110mUSD
Nov 12, Last price
77.60TWD
Name
SYN-Tech Chem & Pharm Co Ltd
Chart & Performance
P/E
8.80
P/S
2.75
EPS
8.82
Div Yield, %
4.51%
Shrs. gr., 5y
7.50%
Rev. gr., 5y
5.85%
Revenues
1.26b
+12.83%
Net income
393m
+56.68%
CFO
623m
+137.38%
Dividend
Jul 19, 20243.5 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
SYN-TECH Chem. & Pharm. Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) in Taiwan and internationally. The company offers products in various categories, such as anticoagulant, attention deficit hyperactivity disorder, skeletal muscle relaxant, antitussive, antipruritic, scabicide, anti-inflammatory, antipyretic, analgesic, muscle relaxant, anxiolytic, antiemetic, anticonvulsant, antiulcerative, dipeptidyl peptidase 4 inhibitor/antidiabetic, antihyertensive, a- blocker, vasodilator, bronchodilator, anxiolytic, tranquilizer, local anesthetic, decongestant, antispasmodic, neuroprotective, antimigraine, hvponatremia, antiglaucoma agent, pharmaceutic aid / lubricant, sedative, and analgesic. SYN-TECH Chem. & Pharm. Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||